Prevalence of human papillomavirus infection in women in Benin, West Africa

Virology Journal

Paola Sirigu⁵  Cristina Maxia⁵  Marco Pittau¹  Manuela Atzori¹  Daniela Murtas⁵  Maria T Perra⁵  Luigi Minerba³  Ahissou RF Zannou⁴  Antonella De Montis¹  Michela Piga²  Franca Piras⁵ 

[1] Research Laboratories, bcs Biotech S.p.A., Cagliari, Italy;Department of Pathology, SS. Trinità Hospital, Cagliari, Italy;Department of Public Health, University of Cagliari, Cagliari, Italy;Ministère de la Santé, Cotonou, Bénin;Department of Cytomorphology, University of Cagliari, Cagliari, Italy

关键词: prevention;    Pap test;    Benin;    cervical cancer;    human papillomavirus;   

Others  :  1155635
DOI  :  10.1186/1743-422X-8-514

 received in 2011-06-23, accepted in 2011-11-10,  发布年份 2011

【 摘 要 】

Background

Cervical cancer ranks as the first most frequent cancer among women in Benin. The major cause of cervical cancer now recognized is persistent infection of Human Papillomavirus (HPV). In Benin there is a lack of screening programs for prevention of cervical cancer and little information exists regarding HPV genotype distribution.

Methods

Cervical cells from 725 women were examined for the presence of viral DNA by means of a polymerase chain reaction (PCR) multiplex-based assay with the amplification of a fragment of L1 region and of E6/E7 region of the HPV genome, and of abnormal cytology by Papanicolaou method. The association between HPV status and Pap test reports was evaluated. Socio-demographic and reproductive characteristics were also related.

Results

A total of 18 different HPV types were identified, with a prevalence of 33.2% overall, and 52% and 26.7% among women with and without cervical lesions, respectively. Multiple HPV infections were observed in 40.2% of HPV-infected women. In the HPV-testing group, the odds ratio for the detection of abnormal cytology was 2.98 (95% CI, 1.83-4.84) for HPV positive in comparison to HPV negative women. High risk types were involved in 88% of infections, most notably HPV-59, HPV-35, HPV-16, HPV-18, HPV-58 and HPV-45. In multiple infections of women with cytological abnormalities HPV-45 predominated.

Conclusions

This study provides the first estimates of the prevalence of HPV and type-specific distribution among women from Benin and demonstrates that the epidemiology of HPV infection in Benin is different from that of other world regions. Specific area vaccinations may be needed to prevent cervical cancer and the other HPV-related diseases.

【 授权许可】

   
2011 Piras et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre): [http://www.who.int/hpvcentre] webciteHuman Papillomavirus and Related Cancers, Benin. Summary Report. 2010.
• [2]Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA: HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
• [3]Kling M, Zeichner JA: The role of the human papillomavirus (HPV) vaccine in developing countries. Int J Dermatol 2010, 49:377-379.
• [4]Sankaranarayanan R, Budukh A, Rajkumar R: Effective screening programs for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001, 79:954-962.
• [5]Katz IT, Wright AA: Preventing cervical cancer in the developing world. N Engl J Med 2006, 354:1110.
• [6]Peto J, Gilham C, Fletcher O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364:249-256.
• [7]zur Hausen H: Infections Causing Human Cancer. Weinheim: WILEY-VCH Verlag GmbH & Co. KgaA; 2006.
• [8]Lizano M, Berumen J, García-Carrancá A: HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res 2009, 40:428-434.
• [9]Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
• [10]Tornesello ML, Duraturo ML, Buonaguro L, Vallefuoco G, Piccoli R, Palmieri S, Buonaguro FM: Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer 2007, 2:1. BioMed Central Full Text
• [11]Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N, Forum Group Members, Bethesda 2001 Workshop: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
• [12]Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson : 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287:2120-2129.
• [13]Societa' Italiana di Colposcopia e Patologia Cervico Vaginale: Gestione della paziente con il Pap-test anormale. Linee Guida Edizione 2006. In La Colposcopia in Italia. Modena: Artioli Editore Poligrafico Artioli; 2006.
• [14]Bishop A, Sherris J, Tsu V: Cervical Dysplasia Treatment in Developing Countries: a Situation Analysis. Seattle: PATH; 1995.
• [15]Bishop A, Wells E, Sherris J, Tsu V, Crook B: Cervical cancer: evolving prevention strategies for developing countries. Reproductive Health Matters 1995, 6:60-71.
• [16]McIntosh N, Blumenthal P, Blouse A: Cervical Cancer Prevention Guidelines for Low-resource Settings. Baltimore: JHPIEGO Corporation; 2001.
• [17]Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007, 4:201-222.
• [18]Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ: Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009, 46(Suppl 3):S1-4.
• [19]Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM: Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989, 7:209-214.
• [20]de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ: The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995, 76:1057-1062.
• [21]Clavel C, Rihet S, Masure M, Chypre C, Boulanger JC, Quereux C, Birembaut P: DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR. J Clin Pathol 1998, 51:38-43.
• [22]Hubbard RA: Human papillomavirus testing methods. Arch Pathol Lab Med 2003, 127:940-945.
• [23]Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239:487-491.
• [24]Clifford GM, Smith JS, Aguado T, Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89:101-105.
• [25]Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73.
• [26]Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, IARC HPV Prevalence Surveys Study Group: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
• [27]Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1157-1164.
• [28]de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases 2007, 7:453-459.
• [29]Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N: Epidemiology and natural history of human papillomavirus infection and type-specific implications in cervical neoplasia. Vaccine 2008, 26:K1-16.
• [30]Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Muñoz N, Snijders PJ, Meijer CJ, Franceschi S: Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004, 90:638-645.
• [31]Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Vallès X, Ouedraogo A, Konate I, Weiss HA, Van de Perre P, Mayaud P, Segondy M, Yerelon Study Group: Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer 2006, 95:355-362.
• [32]Barzon L, Giorgi C, Buonaguro FM, Palù G: Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infectious Agents and Cancer 2008, 3:14. BioMed Central Full Text
• [33]de Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Muñoz N, Català I, Meijer CJ, Snijders PJ, Herrero R, Bosch FX: Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003, 30:788-793.
• [34]Harper DM, Williams KB: Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010, 10:7-17.
• [35]Rhee JE, Shin MY, Kim CM, Kee HY, Chung JK, Min SK, Kim SJ, Jang DH, Kim SS, Choi BS: Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development. Virol J 2010, 7:201. BioMed Central Full Text
• [36]Harper DM: Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy 2008, 5:313-324.
• [37]Haug CJ: Human papillomavirus vaccination--reasons for caution. N Engl J Med 2008, 359:861-862.
• [38]Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.